trending Market Intelligence /marketintelligence/en/news-insights/trending/yajgnny-adskza0sfq0mkw2 content esgSubNav
In This List

Amphastar's generic calcium chloride injection secures US FDA approval

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Amphastar's generic calcium chloride injection secures US FDA approval

Amphastar Pharmaceuticals Inc. said the U.S. Food and Drug Administration approved its generic calcium chloride injection.

The Rancho Cucamonga, Calif.-based specialty pharmaceutical company said the U.S. regulator approved the abbreviated new drug application for calcium chloride injection 10% in the 10-milliliter Luer-Jet Prefilled Syringe System.

Amphastar said it has been selling the product for the past 40 years under the grandfather exception to the FDA's Prescription Drug Wrap-Up program, and net revenues were $13.5 million for the year ended Dec. 31, 2017.